Literature DB >> 11269550

Surgical management of peptic ulcer disease in the Helicobacter era--management of bleeding peptic ulcer.

R A Cowles1, M W Mulholland.   

Abstract

Bleeding continues to be a significant cause of morbidity and mortality for patients with peptic ulcer disease. Recent advances have changed the management of this disease. Upper endoscopy with or without endoscopic therapy is the preferred procedure during the initial evaluation of upper gastrointestinal bleeding. With its excellent success rates, many patients are being cured with endoscopic therapy followed by eradication of Helicobacter pylori. H. pylori is now thought to have an important role in the pathogenesis of a majority of gastric and duodenal ulcers. This finding has led to the recommendation that patients with peptic ulcer disease be treated with regimens effective against this organism. Currently, patients who are older and who have more severe underlying medical conditions present a challenge. This review will address the options for treatment of peptic ulcer bleeding. In addition, knowledge gained regarding H. pylori infection and use of nonsteroidal anti-inflammatory drugs will be discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11269550

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  3 in total

1.  Short- and long-term outcomes of surgical management of peptic ulcer complications in the era of proton pump inhibitors.

Authors:  Rabea Hasadia; Yael Kopelman; Oded Olsha; Ricardo Alfici; Itamar Ashkenazi
Journal:  Eur J Trauma Emerg Surg       Date:  2018-01-22       Impact factor: 3.693

2.  Epidemiology of surgically treated gastric cancer in the United States, 1988-2000.

Authors:  Reid M Wainess; Justin B Dimick; Gilbert R Upchurch; John A Cowan; Michael W Mulholland
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

Review 3.  Current therapy for nonvariceal upper gastrointestinal bleeding.

Authors:  J M Blocksom; S Tokioka; C Sugawa
Journal:  Surg Endosc       Date:  2003-11-21       Impact factor: 4.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.